FSSAI initiates legal action against Nestle India over infant nutrition products

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

The food safety authority examined Nestle’s NAN Excella Pro Stage 1, Lactogen Pro 1, and a follow-up formula along with their promotional material available on e-commerce platforms | Photo Credit: Reuters

The Food Safety and Standards Authority of India (FSSAI) on Friday (September 18, 2026) said it has initiated legal action against Nestle India Ltd for alleged non-compliance with food safety norms in three infant nutrition products.

According to FSSAI, it examined NAN Excella Pro Stage 1, Lactogen Pro 1, and a follow-up formula along with their promotional material available on e-commerce platforms.

In NAN Excella Pro Stage 1, the regulator flagged claims relating to "5HMOs" and "Whey Protein," while in Lactogen Pro 1, it observed a claim describing "Whey Protein" as easy to digest, the regulator said in a social media post.

FSSAI said it had sought clarifications from Nestle India on these claims.

“Our products are fully compliant with all the applicable regulations. The said products (i.e., NAN EXCELLA PRO & LACTOGEN PRO) and their labels were approved by the expert committee of FSSAI. In response to the notice, we have again submitted our detailed response to the authorities regarding statements appearing on the label, which are factual in nature, and supported by scientific literature.” a Nestle spokesperson said.

Both the products were found to be in contravention of Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, which restrict promotional claims or material aimed at increasing the saleability of infant foods, as well as Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, which bars the advertisement or promotion of such products.

Separately, a sample of a follow-up formula manufactured by Nestle India was found sub-standard for Biotin content during laboratory analysis. The sample was sent for re-analysis, and the referral laboratory also found it non-conforming with the Biotin requirement prescribed under the 2020 regulations.

“We confirm to adherence of all regulations including all norms and label declarations as per applicable laws. We will continue to work closely and support FSSAI in its efforts towards consumer awareness.” The Nestle spokesperson added.

In light of these findings, FSSAI has filed three separate adjudication cases against Nestle India in respect of the three products, it added.

At 1:10 p.m., shares of Nestle India were down nearly 2% at ₹1,345.45 on the BSE.

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.